1. Home
  2. ARTL vs BDRX Comparison

ARTL vs BDRX Comparison

Compare ARTL & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

N/A

Current Price

$2.35

Market Cap

1.4M

Sector

Health Care

ML Signal

N/A

Logo Biodexa Pharmaceuticals plc

BDRX

Biodexa Pharmaceuticals plc

SELL

Current Price

$3.86

Market Cap

1.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ARTL
BDRX
Founded
2011
2000
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4M
1.6M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
ARTL
BDRX
Price
$2.35
$3.86
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
32.3K
★ 1.0M
Earning Date
11-11-2026
09-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.52
$0.34
52 Week High
$179.19
$8.94

Technical Indicators

Market Signals
Indicator
ARTL
BDRX
Relative Strength Index (RSI) 32.73 82.72
Support Level $0.52 $2.97
Resistance Level $6.81 $4.39
Average True Range (ATR) 0.17 0.19
MACD 0.03 0.45
Stochastic Oscillator 18.33 88.67

Price Performance

Historical Comparison
ARTL
BDRX

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About BDRX Biodexa Pharmaceuticals plc

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

Share on Social Networks: